Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Niteen Milak

Cardiovascular Disease Bel Air, MD Medical Doctor

NPI 1669466850 CMS profile 120356

520 Upper Chesapeake Dr, Suite 201, Bel Air, MD 21014

Open in the dashboard

General payments

$14,947

678 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Niteen Milak of Bel Air, MD is reported in the CMS Open Payments database as having received $14,947 across 678 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,116 62
2024 General $1,877 90
2023 General $2,551 121
2022 General $1,918 80
2021 General $1,982 91
2020 General $1,510 78
2019 General $2,992 156

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Niteen Milak
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Niteen Milak were reported at $2,116. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Niteen Milak Cardiovascular Disease median Middle half National median
2019 $2,992 $450 $127–$1,392 $163
2020 $1,510 $242 $77–$751 $114
2021 $1,982 $335 $101–$1,037 $132
2022 $1,918 $395 $121–$1,211 $149
2023 $2,551 $443 $136–$1,283 $160
2024 $1,877 $450 $136–$1,323 $164
2025 $2,116 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $3,671 157 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $1,454 57 payments
  3. Janssen Pharmaceuticals, Inc $1,363 68 payments
  4. Amgen Inc. $1,195 57 payments
  5. AstraZeneca Pharmaceuticals LP $1,058 61 payments
  6. Novartis Pharmaceuticals Corporation $886 54 payments
  7. AOP Health US, LLC $675 1 payment
  8. Pfizer Inc. $620 43 payments
  9. Amarin Pharma Inc. $606 23 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $547 43 payments
  11. Other $2,871 114 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,898 674 payments
  2. Education $49 4 payments
Products named General payments · program years 2019–2025
  1. ELIQUIS $2,388 106 payments
  2. XARELTO $1,358 67 payments
  3. Repatha $1,181 56 payments
  4. CAMZYOS $1,129 48 payments
  5. Rapiblyk Cardiovascular $675 1 payment
  6. Rapiblyk Cardiovascular $675 1 payment
  7. BRILINTA $623 38 payments
  8. VERQUVO $568 31 payments
  9. LifeVest $547 43 payments
  10. JARDIANCE $487 8 payments
  11. Other $6,329 314 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

4,591

Median for Cardiology: 2,533

Drug cost

$1,111,291

Median for Cardiology: $485,213

Branded share of claims

25.4%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 350 $477,927
Jardiance Empagliflozin Brand 141 $186,781
Xarelto Rivaroxaban Brand 117 $143,941
Entresto Sacubitril/Valsartan Brand 87 $113,669
Farxiga Dapagliflozin Propanediol Brand 23 $33,914
Vascepa Icosapent Ethyl Brand 34 $26,601
Repatha Sureclick Evolocumab Brand 13 $18,990
Brilinta Ticagrelor Brand 14 $17,207
Repatha Syringe Evolocumab Brand 16 $15,662
Nexletol Bempedoic Acid Brand 16 $11,971

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$241,604

Of which drugs: $3,308

Medicare patients

2,667

Average age 75

Services billed

6,835

1,437 women, 1,230 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 50%
Diabetes 41%
Atrial fibrillation 37%
Chronic kidney disease 37%
Heart failure 32%
Depression 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 46 172 $591

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $295
  • PFIZER INC. $13
$308 350 —
Repatha
  • Amgen Inc. $182
$182 29 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $152
$152 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $151
$151 — —
FUROSCIX
  • SCPHARMACEUTICALS INC. $132
$132 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

678 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record